Acer Therapeutics GAAP EPS of -$0.31 misses by $0.30, revenue of $0.36M misses by $2.97M
- Acer Therapeutics press release (NASDAQ:ACER): Q4 GAAP EPS of -$0.31 misses by $0.30.
- Revenue of $0.36M misses by $2.97M.
- Ended Q4 2021 with $12.7 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of December 31, 2021.